1352568-41-2

Upstream product

• 405229-64-3 (2R,4S)-1-tert-butyl 2-methyl 4-(methylsulfonyloxy)piperidine-1,2-dicarboxylate 
• 321744-26-7 N-Boc-4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 1352568-40-1 C₂₀H₂₈N₂O₆ 
• 778646-95-0 (2R,4R)-1-tert-butyl 2-methyl 4-aminopiperidine-1,2-dicarboxylate 
• 1095173-08-2 (2R,4R)-1-tert-butyl 2-methyl 4-azidopiperidine-1,2-dicarboxylate 

Downstream Products

• 1352568-43-4 C₂₁H₂₄N₄O₂ 
• 1352568-42-3 C₂₅H₃₂N₄O₅ 

Relevant academic research and scientific papers

Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened

Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncology area due to the mounting evidence of their potential to provide promising therapeutic options for patients. Herein, we describe the discovery strategy to overcome the issues inherent in lead structure 1 that resulted in the identification of Smoothened inhibitor 1-((2R,4R)-2-(1H-benzo[d] imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clinical studies.